Unknown

Dataset Information

0

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.


ABSTRACT: Precision medicine refers to a highly individualized and personalized approach to patient care. Pharmacogenomics is the study of how an individual's genomic profile affects their drug response, enabling stable and effective drug selection, minimizing side effects, and maximizing therapeutic efficacy. Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation in the joints. It mainly starts in peripheral joints, such as the hands and feet, and progresses to large joints, which causes joint deformation and bone damage due to inflammation of the synovial membrane. Here, we review various pharmacogenetic studies investigating the association between clinical response to monoclonal antibody therapy and their target genetic polymorphisms. Numerous papers have reported that some single nucleotide polymorphisms (SNPs) are related to the therapeutic response of several monoclonal antibody drugs including adalimumab, infliximab, rituximab, and tocilizumab, which target tumor necrosis factor (TNF), CD20 of B-cells, and interleukin (IL)-6. Additionally, there are some pharmacogenomic studies reporting on the association between the clinical response of monoclonal antibodies having various mechanisms, such as IL-1, IL-17, IL-23, granulocyte-macrophage colony-stimulating factor (GM-CSF) and the receptor activator of nuclear factor-kappa B (RANK) inhibition. Biological therapies are currently prescribed on a "trial and error" basis for RA patients. If appropriate drug treatment is not started early, joints may deform, and long-term treatment outcomes may worsen. Pharmacogenomic approaches that predict therapeutic responses for RA patients have the potential to significantly improve patient quality of life and reduce treatment costs.

SUBMITTER: Lim SH 

PROVIDER: S-EPMC9410311 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.

Lim Sung Ho SH   Kim Khangyoo K   Choi Chang-Ik CI  

Journal of personalized medicine 20220731 8


Precision medicine refers to a highly individualized and personalized approach to patient care. Pharmacogenomics is the study of how an individual's genomic profile affects their drug response, enabling stable and effective drug selection, minimizing side effects, and maximizing therapeutic efficacy. Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation in the joints. It mainly starts in peripheral joints, such as the hands and feet, and progresses to large joints,  ...[more]

Similar Datasets

| S-EPMC3057286 | biostudies-literature
| S-EPMC6719675 | biostudies-literature
| PRJNA294477 | ENA
| S-EPMC8879844 | biostudies-literature
| S-EPMC8294326 | biostudies-literature
| S-EPMC9325258 | biostudies-literature
| S-EPMC7854072 | biostudies-literature
2010-01-28 | GSE19821 | GEO
2010-06-24 | E-GEOD-19821 | biostudies-arrayexpress
| S-EPMC400433 | biostudies-literature